Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLDXNASDAQ:FOLDNASDAQ:IONSNASDAQ:LGND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$15.63-4.8%$20.27$14.40▼$47.00$1.04B1.59875,601 shs338,176 shsFOLDAmicus Therapeutics$6.29-8.8%$8.84$6.20▼$12.65$1.93B0.792.58 million shs1.72 million shsIONSIonis Pharmaceuticals$25.97-6.5%$31.41$23.95▼$52.34$4.13B0.291.49 million shs637,205 shsLGNDLigand Pharmaceuticals$99.37-4.3%$111.33$67.72▼$129.90$1.91B1.07111,092 shs56,343 shsUnlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics+8.46%-5.58%-16.10%-38.15%-59.60%FOLDAmicus Therapeutics+2.53%-13.77%-20.16%-27.17%-41.36%IONSIonis Pharmaceuticals+8.86%-3.27%-13.81%-18.56%-35.16%LGNDLigand Pharmaceuticals+7.43%-4.49%-4.99%-6.09%+27.42%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLDXCelldex Therapeutics2.4693 of 5 stars4.43.00.00.02.70.00.0FOLDAmicus Therapeutics4.0686 of 5 stars3.41.00.04.33.40.81.9IONSIonis Pharmaceuticals4.115 of 5 stars4.42.00.03.02.12.50.6LGNDLigand Pharmaceuticals4.3915 of 5 stars3.51.00.04.43.52.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDXCelldex Therapeutics 2.89Moderate Buy$54.33247.69% UpsideFOLDAmicus Therapeutics 2.78Moderate Buy$16.75166.51% UpsideIONSIonis Pharmaceuticals 2.70Moderate Buy$56.72118.43% UpsideLGNDLigand Pharmaceuticals 3.00Buy$146.4347.36% UpsideCurrent Analyst Ratings BreakdownLatest CLDX, IONS, FOLD, and LGND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025LGNDLigand PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$143.004/8/2025IONSIonis PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.004/7/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$45.004/7/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$45.004/3/2025IONSIonis PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/31/2025IONSIonis PharmaceuticalsRedburn AtlanticSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$39.003/24/2025IONSIonis PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$47.00 ➝ $45.003/20/2025CLDXCelldex TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$46.003/11/2025IONSIonis PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$51.00 ➝ $47.003/3/2025CLDXCelldex TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$42.00 ➝ $36.002/28/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00(Data available from 4/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDXCelldex Therapeutics$7.02M147.78N/AN/A$9.08 per share1.72FOLDAmicus Therapeutics$528.30M3.66N/AN/A$0.63 per share9.98IONSIonis Pharmaceuticals$705.14M5.85N/AN/A$3.70 per share7.02LGNDLigand Pharmaceuticals$167.13M11.45$4.07 per share24.39$40.39 per share2.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDXCelldex Therapeutics-$141.43M-$2.45N/AN/AN/A-1,544.32%-19.75%-18.86%5/5/2025 (Estimated)FOLDAmicus Therapeutics-$151.58M-$0.18N/A14.621.51-10.62%12.44%2.60%5/8/2025 (Estimated)IONSIonis Pharmaceuticals-$366.29M-$3.04N/AN/AN/A-64.25%-100.05%-15.70%5/6/2025 (Estimated)LGNDLigand Pharmaceuticals$52.15M-$0.1639.5926.78N/A29.68%4.95%4.39%5/6/2025 (Estimated)Latest CLDX, IONS, FOLD, and LGND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025FOLDAmicus Therapeutics$0.08N/AN/AN/A$136.32 millionN/A5/6/2025Q1 2025IONSIonis Pharmaceuticals-$1.07N/AN/AN/A$144.31 millionN/A5/6/2025Q1 2025LGNDLigand Pharmaceuticals$1.23N/AN/AN/A$37.84 millionN/A5/5/2025Q1 2025CLDXCelldex Therapeutics-$0.75N/AN/AN/A$1.08 millionN/A2/27/2025Q4 2024CLDXCelldex Therapeutics-$0.73-$0.71+$0.02-$0.71$1.25 million$1.18 million2/19/2025Q4 2024IONSIonis Pharmaceuticals-$1.12-$0.66+$0.46-$0.66$140.97 million$227.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDXCelldex TherapeuticsN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDXCelldex TherapeuticsN/A24.2724.27FOLDAmicus Therapeutics2.013.392.42IONSIonis Pharmaceuticals2.128.478.82LGNDLigand PharmaceuticalsN/A12.4911.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDXCelldex TherapeuticsN/AFOLDAmicus TherapeuticsN/AIONSIonis Pharmaceuticals93.86%LGNDLigand Pharmaceuticals91.28%Insider OwnershipCompanyInsider OwnershipCLDXCelldex Therapeutics3.80%FOLDAmicus Therapeutics2.20%IONSIonis Pharmaceuticals2.71%LGNDLigand Pharmaceuticals5.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDXCelldex Therapeutics15066.38 million63.82 millionOptionableFOLDAmicus Therapeutics480307.24 million292.23 millionOptionableIONSIonis Pharmaceuticals800158.97 million153.62 millionOptionableLGNDLigand Pharmaceuticals8019.26 million17.78 millionOptionableCLDX, IONS, FOLD, and LGND HeadlinesRecent News About These CompaniesThis Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayApril 10 at 10:28 AM | benzinga.comLigand Pharmaceuticals (NASDAQ:LGND) Cut to Sell at StockNews.comApril 9 at 11:09 PM | marketbeat.comMassachusetts Financial Services Co. MA Takes Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)April 8 at 4:47 AM | marketbeat.comFranklin Resources Inc. Purchases 90,743 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)April 8 at 4:19 AM | marketbeat.comVanguard Group Inc. Buys 115,005 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)April 7 at 3:27 AM | marketbeat.com3,900 Shares in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Acquired by KLP Kapitalforvaltning ASApril 6, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Short Interest UpdateApril 4, 2025 | marketbeat.comShort Interest in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Grows By 22.4%April 3, 2025 | americanbankingnews.comRaymond James Financial Inc. Makes New $2.34 Million Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)March 30, 2025 | marketbeat.comLoomis Sayles & Co. L P Purchases 24,921 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)March 29, 2025 | marketbeat.comVirtu Financial LLC Takes $338,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)March 29, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Recommendation of "Buy" from AnalystsMarch 27, 2025 | marketbeat.comCongress Wealth Management LLC DE Purchases 4,014 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)March 25, 2025 | marketbeat.com4,418 Shares in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Purchased by Summit Global InvestmentsMarch 25, 2025 | marketbeat.comRoyce & Associates LP Sells 3,193 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)March 23, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Increases Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)March 20, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Sells 3,200 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)March 19, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Acquired by AmundiMarch 19, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Rating Increased to Hold at StockNews.comMarch 18, 2025 | marketbeat.comBank of New York Mellon Corp Sells 4,847 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)March 13, 2025 | marketbeat.comCallan Family Office LLC Takes Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)March 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesNVIDIA Insiders Sell: This Is What It Means for the Market By Thomas Hughes | March 25, 2025View NVIDIA Insiders Sell: This Is What It Means for the Market 3 Energy Stocks With Cheap Valuations and Big Returns AheadBy Sarah Horvath | March 19, 2025View 3 Energy Stocks With Cheap Valuations and Big Returns AheadSuper Micro Stock: $7.2M Call Options Signal Big Upside PotentialBy Gabriel Osorio-Mazilli | March 24, 2025View Super Micro Stock: $7.2M Call Options Signal Big Upside PotentialCould Palantir’s R1 Deal Be the Catalyst for a Stock Surge?By Chris Markoch | March 21, 2025View Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?D-Wave Quantum Stock Jumps on "Quantum Supremacy" NewsBy Chris Markoch | March 14, 2025View D-Wave Quantum Stock Jumps on "Quantum Supremacy" NewsCLDX, IONS, FOLD, and LGND Company DescriptionsCelldex Therapeutics NASDAQ:CLDX$15.63 -0.78 (-4.77%) As of 01:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Amicus Therapeutics NASDAQ:FOLD$6.28 -0.61 (-8.78%) As of 01:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Ionis Pharmaceuticals NASDAQ:IONS$25.97 -1.80 (-6.49%) As of 01:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.Ligand Pharmaceuticals NASDAQ:LGND$99.37 -4.48 (-4.31%) As of 01:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom's Big Outperformance Shows Strength Amid Tariff Decline Delta, Walmart Cut Profit Targets: Could Start Domino Effect Joby Aviation: Operational Momentum vs. Market Sentiment Carvana: Can Turnaround Strength Outdrive Market Headwinds? Is Alphabet a Generational Buying Opportunity at These Levels? Meta Seeks Trump's Help in FTC Trial: The Implications Are Huge Is Microsoft Stock Too Cheap to Ignore After Its Latest Drop? Harley-Davidson Tops Watchlists: Value Trap or Turnaround Play? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
